---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Idecabtagene Vicleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/idecabtagenevicleucel
version: v1
---

# Idecabtagene Vicleucel - NCI

# Idecabtagene Vicleucel

Placeholder slot

(I-deh-KAB-tuh-jeen vik-LOO-sel)

This page contains brief information about idecabtagene vicleucel
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Abecma

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c&audience=consumer)

## Use in Cancer

Idecabtagene vicleucel
is approved to treat:

- **[multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English)** that has come back or did not respond to treatment. It is used in adults who have received at least two lines of treatment that included an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English), a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English), and an [anti-CD38 monoclonal antibody](/Common/PopUps/popDefinition.aspx?id=798792&version=Patient&language=English)

It is used in adults who have received at least two lines of treatment that included an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English), a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English), and an [anti-CD38 monoclonal antibody](/Common/PopUps/popDefinition.aspx?id=798792&version=Patient&language=English).

Idecabtagene vicleucel is only available as part of a program called Abecma REMS ([Risk Evaluation and Mitigation Strategies](https://www.abecmarems.com/)).

## More About Idecabtagene Vicleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/763837) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Idecabtagene Vicleucel](https://medlineplus.gov/druginfo/meds/a621024.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Understanding the Risk of Second Cancers After CAR T-Cell Therapy](https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[T-cell Transfer Therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)

[CAR T Cells: Engineering Patientsâ€™ Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Idecabtagene Vicleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C117729) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
